Last reviewed · How we verify
CAB-AXL-ADC
CAB-AXL-ADC is a Antibody-drug conjugate (ADC) Biologic drug developed by BioAtla, Inc.. It is currently in Phase 2 development for AXL-positive solid tumors (Phase 2 development). Also known as: BA3011.
CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding.
CAB-AXL-ADC is an antibody-drug conjugate that targets AXL-expressing cancer cells and delivers cytotoxic payload upon binding. Used for AXL-positive solid tumors (Phase 2 development).
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CAB-AXL-ADC |
|---|---|
| Also known as | BA3011 |
| Sponsor | BioAtla, Inc. |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | AXL |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
CAB-AXL-ADC combines a monoclonal antibody against AXL (a receptor tyrosine kinase) with a cytotoxic drug payload. Upon binding to AXL on tumor cells, the conjugate is internalized and releases the toxic payload to kill cancer cells. This approach aims to selectively target AXL-positive tumors while minimizing systemic toxicity.
Approved indications
- AXL-positive solid tumors (Phase 2 development)
Common side effects
- Nausea
- Fatigue
- Thrombocytopenia
- Anemia
Key clinical trials
- Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (PHASE2)
- CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC (PHASE2)
- CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAB-AXL-ADC CI brief — competitive landscape report
- CAB-AXL-ADC updates RSS · CI watch RSS
- BioAtla, Inc. portfolio CI
Frequently asked questions about CAB-AXL-ADC
What is CAB-AXL-ADC?
How does CAB-AXL-ADC work?
What is CAB-AXL-ADC used for?
Who makes CAB-AXL-ADC?
Is CAB-AXL-ADC also known as anything else?
What drug class is CAB-AXL-ADC in?
What development phase is CAB-AXL-ADC in?
What are the side effects of CAB-AXL-ADC?
What does CAB-AXL-ADC target?
Related
- Drug class: All Antibody-drug conjugate (ADC) drugs
- Target: All drugs targeting AXL
- Manufacturer: BioAtla, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for AXL-positive solid tumors (Phase 2 development)
- Also known as: BA3011
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing